← Trials/Trial dossier/NCT05561205

REACT

RecruitingPhase NA

rTMS for Apathy Clinical Trial

Repetitive Transcranial Magnetic Stimulation for Apathy Clinical Trial (REACT)

Lead sponsor

Sunnybrook Health Sciences Centre

Asset

Methylphenidate

Listed sites

Recruiting sites

Enrollment

estimated

Study population

Alzheimer’s disease, MCI / preclinical Alzheimer’s

Key I/E criterion

Primary endpoint

•Neuropsychiatric Inventory (NPI)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05561205

Org study IDSUN-5342

Timeline

Milestones

Study first posted2022-09-30actual

Study start2023-02-09actual

Last update posted2026-04-13actual

Primary completion2026-12-01estimated

Study completion2026-12-01estimated

Assets

Drug assets

Methylphenidate

Study populations

Who this study enrolls

Alzheimer’s diseaseMCI / preclinical Alzheimer’s

Eligibility

Who can enroll

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•mild or major neurocognitive disorder OR mild behavioural impairment

•Apathy for at least 4 weeks

•Stable dose of medication (>4 weeks) that may affect cognition or behaviour

•Care partner who spends at least 10 hours a week with the subject

Exclusion criteria

•Current major depressive episode

•Agitation, delusions, hallucination

•Medical contraindications to rTMS

•Currently taking an amphetamine product

•Central nervous system abnormalities, Tourette's syndrome, or motor tics

•Current participation in another clinical trial

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Behavior / neuropsychiatric

1 endpoint

Primary/protocol endpoint

Neuropsychiatric Inventory-apathy

Time frame:2 weeks

Neuropsychiatric Inventory (NPI)

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.